{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T22:50:59Z","timestamp":1787352659089,"version":"build-2736575974"},"reference-count":210,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.blre.2024.101218","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T15:55:35Z","timestamp":1717430135000},"page":"101218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide"],"prefix":"10.1016","volume":"66","author":[{"given":"Clifton C.","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Calabretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet H.","family":"Kocoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca M.","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marie","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Iacobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Jen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"D\u00edaz-Ricart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Moraleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2024.101218_bb0005","author":"World Health Organization"},{"key":"10.1016\/j.blre.2024.101218_bb0010","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/S1473-3099(21)00703-9","article-title":"A clinical case definition of post-COVID-19 condition by a Delphi consensus","volume":"22","author":"Soriano","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.blre.2024.101218_bb0015","doi-asserted-by":"crossref","DOI":"10.1172\/JCI161167","article-title":"Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches","volume":"132","author":"Ahamed","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2024.101218_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020379","article-title":"COVID-19 outcomes in patients with hematologic malignancies in the era of COVID-19 vaccination and the omicron variant","volume":"16","author":"Martinez-Lopez","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2024.101218_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051497","article-title":"COVID-19 severity and survival over time in patients with hematologic malignancies: a population-based registry study","volume":"15","author":"Martinez-Lopez","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2024.101218_bb0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0288","article-title":"Severe COVID-19 in vaccinated adults with hematologic cancers in the veterans health administration","volume":"7","author":"Anand","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.blre.2024.101218_bb0035","article-title":"Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: an age-matched cohorts study","volume":"13","author":"Fernandez-Cruz","year":"2022","journal-title":"Clin Infect Pract"},{"key":"10.1016\/j.blre.2024.101218_bb0040","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/bjh.17937","article-title":"Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy","volume":"196","author":"Booth","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101218_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113603","article-title":"Effectiveness and safety of COVID-19 vaccination in people with blood cancer","volume":"201","author":"Copland","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2024.101218_bb0050","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1093\/infdis\/jiad174","article-title":"COVID-19 vaccination in patients with cancer and patients receiving HSCT or CAR-T therapy: immune response, real-world effectiveness, and implications for the future","volume":"228","author":"Hall","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.blre.2024.101218_bb0055","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3324\/haematol.2011.054015","article-title":"Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2024.101218_bb0060","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/blood-2023-187568","article-title":"Impact of COVID 19 on patients with multiple myeloma: a national inpatient sample analysis","volume":"142","author":"Sanghvi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0065","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41408-021-00588-z","article-title":"Impact of COVID-19 in patients with multiple myeloma based on a global data network","volume":"11","author":"Martinez-Lopez","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2024.101218_bb0070","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/2643-3230.BCD-20-0102","article-title":"COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers","volume":"1","author":"Hultcrantz","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.blre.2024.101218_bb0075","doi-asserted-by":"crossref","first-page":"e3240","DOI":"10.1002\/hon.3240","article-title":"Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: results from the epicovideha registry","volume":"42","author":"Musto","year":"2024","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.blre.2024.101218_bb0080","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41375-023-01920-1","article-title":"Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)","volume":"37","author":"Terpos","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2024.101218_bb0085","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10238-024-01299-y","article-title":"Causality between COVID-19 and multiple myeloma: a two-sample Mendelian randomization study and Bayesian co-localization","volume":"24","author":"Wang","year":"2024","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.blre.2024.101218_bb0090","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/14740338.2023.2274420","article-title":"A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma","volume":"22","author":"Midha","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.blre.2024.101218_bb0095","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.blre.2024.101218_bb0100","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/14712598.2021.1841747","article-title":"Isatuximab for the treatment of relapsed\/refractory multiple myeloma","volume":"20","author":"Richardson","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.blre.2024.101218_bb0105","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/1078-0432.CCR-22-0618","article-title":"FDA approval summary: belantamab mafodotin for patients with relapsed or refractory multiple myeloma","volume":"28","author":"Baines","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2024.101218_bb0110","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/17512433.2022.2075847","article-title":"Melflufen for the treatment of multiple myeloma","volume":"15","author":"Ocio","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.blre.2024.101218_bb0115","first-page":"1184","article-title":"CAR T-cell therapy for multiple myeloma: a clinical practice-oriented review","volume":"114","author":"Sadek","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2024.101218_bb0120","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.2023022499","article-title":"BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety and resistance mechanisms","volume":"143","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.2022016175","article-title":"Vaccine-induced T-cell responses against SARS-CoV-2 and its omicron variant in patients with B cell-depleted lymphoma after CART therapy","volume":"140","author":"Atanackovic","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0130","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/bloodadvances.2021006112","article-title":"Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy","volume":"6","author":"Dahiya","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101218_bb0135","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101218_bb0140","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/bjh.18066","article-title":"Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell response","volume":"197","author":"Ramasamy","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101218_bb0145","article-title":"Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed\/refractory multiple myeloma: a challenging and happy ending fight","volume":"21","author":"Ielo","year":"2024","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.blre.2024.101218_bb0150","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clml.2023.03.002","article-title":"Response to COVID-19 vaccination post-CAR T therapy in patients with non-Hodgkin lymphoma and multiple myeloma","volume":"23","author":"Wiedmeier-Nutor","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2024.101218_bb0155","first-page":"398","article-title":"Severe acute respiratory syndrome coronavirus 2 vaccine immunogenicity among chimeric antigen receptor T cell therapy recipients","volume":"29","author":"Aleissa","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2024.101218_bb0160","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.38961","article-title":"Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma","volume":"5","author":"Hammons","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.blre.2024.101218_bb0165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/cas.16001","article-title":"Outcomes of COVID-19 in multiple myeloma patients treated with daratumumab","volume":"115","author":"Jin","year":"2024","journal-title":"Cancer Sci"},{"key":"10.1016\/j.blre.2024.101218_bb0170","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ajh.26762","article-title":"Risk factors for severe infection and mortality in patients with COVID-19 in patients with multiple myeloma and AL amyloidosis","volume":"98","author":"Ho","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101218_bb0175","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-023-00901-y","article-title":"Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma","volume":"13","author":"Mitra","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2024.101218_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24098237","article-title":"Endotheliopathy in acute COVID-19 and long COVID","volume":"24","author":"Vassiliou","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2024.101218_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23116196","article-title":"The endothelium and COVID-19: an increasingly clear link brief title: endotheliopathy in COVID-19","volume":"23","author":"Six","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2024.101218_bb0190","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.701","article-title":"The potential link between COVID-19 and multiple myeloma: a new saga","volume":"10","author":"Al-Kuraishy","year":"2022","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.blre.2024.101218_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.620312","article-title":"Toxicities of chimeric antigen receptor T cell therapy in multiple myeloma: an overview of experience from clinical trials, pathophysiology, and management strategies","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2024.101218_bb0200","doi-asserted-by":"crossref","first-page":"E348","DOI":"10.1002\/ajh.24447","article-title":"Proteasome inhibitor associated thrombotic microangiopathy","volume":"91","author":"Yui","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101218_bb0205","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2023-191305","article-title":"Pooled analysis on bispecific antibody-related toxicities in multiple myeloma","volume":"142","author":"Golmohammadi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/cvr\/cvaa085","volume":"117","author":"Alexander","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.blre.2024.101218_bb0215","article-title":"Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications","volume":"10","author":"Palomo","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.blre.2024.101218_bb0220","volume":"58","author":"Chang","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.blre.2024.101218_bb0225","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.16621","article-title":"Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation","volume":"190","author":"Hildebrandt","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101218_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020216","article-title":"Signaling pathway mediating myeloma cell growth and survival","volume":"13","author":"Hideshima","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2024.101218_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113380","article-title":"Cancer-associated angiogenesis: the endothelial cell as a checkpoint for immunological patrolling","volume":"12","author":"Solimando","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2024.101218_bb0240","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3389\/fonc.2020.00815","article-title":"Hyperviscosity syndrome in paraprotein secreting conditions including waldenstrom macroglobulinemia","volume":"10","author":"Weaver","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2024.101218_bb0245","first-page":"214","article-title":"Potential mechanisms of resistance to current anti-thrombotic strategies in multiple myeloma","volume":"5","author":"Comerford","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.blre.2024.101218_bb0250","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1111\/jth.15773","article-title":"The role of VWF\/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies","volume":"20","author":"Comerford","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101218_bb0255","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.kint.2020.11.010","article-title":"Management of acute kidney injury in symptomatic multiple myeloma","volume":"99","author":"Bridoux","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.blre.2024.101218_bb0260","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fendo.2018.00788","article-title":"Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma","volume":"9","author":"Harmer","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.blre.2024.101218_bb0265","article-title":"Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions","volume":"9","author":"Moscvin","year":"2023","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.blre.2024.101218_bb0270","doi-asserted-by":"crossref","first-page":"6859","DOI":"10.1182\/bloodadvances.2023010139","article-title":"HAPLN1 matrikine: a bone marrow homing factor linked to poor outcomes in patients with MM","volume":"7","author":"Chang","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101218_bb0275","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-189255","article-title":"Spatial dissection of the bone marrow microenvironment in multiple myeloma by high dimensional multiplex tissue imaging","volume":"142","author":"Baertsch","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0280","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood-2023-178534","article-title":"Comprehensive characterization of the bone marrow microenvironment transcriptional remodeling in the progression from MGUS to smoldering and multiple myeloma","volume":"142","author":"Cenzano","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0285","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/blood-2023-182968","article-title":"Single cell analysis of bone marrow stromal cells shows that a pro-inflammatory and stress response together with polarized differentiation of stromal elements characterize the bone marrow microenvironment during multiple myeloma development","volume":"142","author":"Ghamlouch","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11113012","article-title":"The clinical relevance of selected cytokines in newly diagnosed multiple myeloma patients","volume":"11","author":"Mielnik","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.blre.2024.101218_bb0295","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s10238-023-01277-w","article-title":"An inflammatory response-related gene signature can predict the prognosis and impact the immune infiltration of multiple myeloma","volume":"24","author":"Zhao","year":"2024","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.blre.2024.101218_bb0300","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-024-00998-9","article-title":"Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems","volume":"14","author":"Guo","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2024.101218_bb0305","first-page":"187","article-title":"Easix score correlates with endothelial dysfunction biomarkers and predicts risk of acute graft-versus-host disease after allogeneic transplantation","volume":"30","author":"Pedraza","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2024.101218_bb0310","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1186\/s12885-020-07317-y","article-title":"Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma","volume":"20","author":"Song","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2024.101218_bb0315","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.immuni.2021.07.002","article-title":"Beta(2)-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression","volume":"54","author":"Hofbauer","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2024.101218_bb0320","article-title":"Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2024.101218_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21145002","article-title":"Cytokine-mediated dysregulation of signaling pathways in the pathogenesis of multiple myeloma","volume":"21","author":"Akhtar","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2024.101218_bb0330","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-021-22804-x","article-title":"Co-evolution of tumor and immune cells during progression of multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2024.101218_bb0335","doi-asserted-by":"crossref","DOI":"10.1111\/ecc.12761","article-title":"Mechanisms of bone destruction in multiple myeloma","volume":"26","author":"Terpos","year":"2017","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.blre.2024.101218_bb0340","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3892\/or.2015.3941","article-title":"Role of chemokine CX3CL1 in progression of multiple myeloma via CX3CR1 in bone microenvironments","volume":"33","author":"Wada","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.blre.2024.101218_bb0345","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood-2023-186645","article-title":"Prothrombotic profile in patients with active multiple myeloma and the impact of immunomodulators: the roadmap-MM study","volume":"142","author":"Van Dreden","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0350","article-title":"The role of blood viscosity in infectious diseases","volume":"12","author":"Sloop","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.blre.2024.101218_bb0355","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1182\/blood-2023-187055","article-title":"Evaluation of clinical risk factors and thrombosis-related biomarkers in newly diagnosed patients with multiple myeloma at risk for cancer-associated thrombosis. The observational roadmat-CAT-MM study","volume":"142","author":"Van Dreden","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0360","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/17474086.2023.2288154","article-title":"Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection","volume":"16","author":"Boccatonda","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2024.101218_bb0365","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/cvr\/cvaa230","article-title":"Endothelial dysfunction in COVID-19: a position paper of the ESC working group for atherosclerosis and vascular biology, and the ESC council of basic cardiovascular science","volume":"116","author":"Evans","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.blre.2024.101218_bb0370","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1164\/rccm.202107-1774OC","article-title":"COVID-19-associated lung microvascular endotheliopathy: a \u201cfrom the bench\u201d perspective","volume":"206","author":"Joffre","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.blre.2024.101218_bb0375","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.17240","article-title":"COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies","volume":"193","author":"Calabretta","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101218_bb0380","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10557-021-07207-w","article-title":"Is the endothelium the missing link in the pathophysiology and treatment of COVID-19 complications?","volume":"36","author":"Castro","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.blre.2024.101218_bb0385","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/s41591-021-01500-9","article-title":"Calming the cytokine storm in COVID-19","volume":"27","author":"Cron","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2024.101218_bb0390","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/SHK.0000000000001823","article-title":"Distinctive biomarker features in the endotheliopathy of COVID-19 and septic syndromes","volume":"57","author":"Fernandez","year":"2022","journal-title":"Shock"},{"key":"10.1016\/j.blre.2024.101218_bb0395","article-title":"NETosis and neutrophil extracellular traps in COVID-19: immunothrombosis and beyond","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2024.101218_bb0400","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250010","article-title":"Neutrophil activation and neutrophil extracellular traps (NETs) in COVID-19 ARDS and immunothrombosis","volume":"53","author":"Cesta","year":"2023","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.blre.2024.101218_bb0405","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/jth.14849","article-title":"Thromboinflammation and the hypercoagulability of COVID-19","volume":"18","author":"Connors","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101218_bb0410","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1213\/ANE.0000000000006214","article-title":"Thrombosis-related loss of arterial lines in the first wave of COVID-19 and non-COVID-19 intensive care unit patients","volume":"136","author":"Zon","year":"2023","journal-title":"Anesth Analg"},{"key":"10.1016\/j.blre.2024.101218_bb0415","article-title":"Changes in the blood viscosity in patients with SARS-CoV-2 infection","volume":"9","author":"Al-Kuraishy","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.blre.2024.101218_bb0420","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1111\/jth.15490","article-title":"Persistent endotheliopathy in the pathogenesis of long COVID syndrome","volume":"19","author":"Fogarty","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101218_bb0425","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.trsl.2022.01.004","article-title":"Post-COVID-19 patients show an increased endothelial progenitor cell production","volume":"243","author":"Poyatos","year":"2022","journal-title":"Transl Res"},{"key":"10.1016\/j.blre.2024.101218_bb0430","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12933-021-01359-7","article-title":"Persistent clotting protein pathology in long COVID\/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin","volume":"20","author":"Pretorius","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.blre.2024.101218_bb0435","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1016\/j.jtha.2023.07.012","article-title":"Uncertainties about the roles of anticoagulation and microclots in postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection","volume":"21","author":"Connors","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101218_bb0440","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-95565-8","article-title":"More than 50 long-term effects of COVID-19: a systematic review and meta-analysis","volume":"11","author":"Lopez-Leon","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2024.101218_bb0445","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment","volume":"22","author":"Dalle","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2024.101218_bb0450","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1050994","article-title":"Early vascular endothelial complications after hematopoietic cell transplantation: role of the endotheliopathy in biomarkers and target therapies development","volume":"13","author":"Moreno-Castano","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2024.101218_bb0455","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.bbmt.2010.02.016","article-title":"Prediction of veno-occlusive disease using biomarkers of endothelial injury","volume":"16","author":"Cutler","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2024.101218_bb0460","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2991\/chi.d.190317.001","article-title":"Endothelial dysfunction in hematopoietic cell transplantation","volume":"1","author":"Palomo","year":"2019","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.blre.2024.101218_bb0465","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000529665","article-title":"Circulating endothelial cell kinetic in patients with multiple myeloma who receive autologous hematopoietic stem cell transplantation","volume":"68","author":"Annibali","year":"2023","journal-title":"Chemotherapy"},{"key":"10.1016\/j.blre.2024.101218_bb0470","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1016\/j.clml.2021.06.004","article-title":"Budesonide prophylaxis reduces the risk of engraftment syndrome after autologous hematopoietic cell transplantation in multiple myeloma","volume":"21","author":"Dhakal","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2024.101218_bb0475","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41409-022-01610-z","article-title":"An endothelial proinflammatory phenotype precedes the development of the engraftment syndrome after autologous Hct","volume":"57","author":"Moreno-Castano","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2024.101218_bb0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: cardiooncology state-of-the-art review","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.blre.2024.101218_bb0485","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310842","article-title":"Bortezomib increased vascular permeability by decreasing cell-cell junction molecules in human pulmonary microvascular endothelial cells","volume":"24","author":"Matsumoto","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2024.101218_bb0490","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1038\/s41409-020-0947-9","article-title":"The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium","volume":"55","author":"Martinez-Sanchez","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2024.101218_bb0495","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15072191","article-title":"Arginase inhibition mitigates bortezomib-exacerbated cardiotoxicity in multiple myeloma","volume":"15","author":"Paterek","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2024.101218_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114907","article-title":"Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway","volume":"164","author":"Dabour","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.blre.2024.101218_bb0505","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2018-06-858415","article-title":"Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin","volume":"133","author":"Efentakis","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0510","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/s41375-021-01141-4","article-title":"Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study","volume":"35","author":"Kastritis","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2024.101218_bb0515","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.112","article-title":"Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?","volume":"6","author":"Rosenthal","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2024.101218_bb0520","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-023-00802-0","article-title":"Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy","volume":"13","author":"Moscvin","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2024.101218_bb0525","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101218_bb0530","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101218_bb0535","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2024.101218_bb0540","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101218_bb0545","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101218_bb0550","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2024.101218_bb0555","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2024.101218_bb0560","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101218_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9113577","article-title":"CAR T-cells in multiple myeloma are ready for prime time","volume":"9","author":"Rodriguez-Otero","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2024.101218_bb0570","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184550","article-title":"Bispecific antibodies in hematological malignancies: a scoping review","volume":"15","author":"Omer","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2024.101218_bb0575","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.blre.2024.101218_bb0580","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41467-023-44648-3","article-title":"Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma","volume":"15","author":"Yang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2024.101218_bb0585","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.blre.2024.101218_bb0590","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.6004\/jnccn.2023.7100","article-title":"Integrating immune therapies for the treatment of multiple myeloma","volume":"21","author":"Mikkilineni","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.blre.2024.101218_bb0595","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood-2023-180283","article-title":"Patterns of cytokine release syndrome with teclistamab in relapsed\/refractory multiple myeloma with or without prior T-cell redirection therapy","volume":"142","author":"Hamadeh","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0600","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2023-182695","article-title":"Adverse effects and non-relapse mortality of BCMA-directed immunotherapies: an FDA adverse event reporting system (FAERS) database study","volume":"142","author":"Gong","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0605","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1182\/blood-2023-174921","article-title":"Real-world incidence, characteristics and management of cytokine release syndrome induced by chimeric antigen receptor T-cell therapy across hematologic malignancies","volume":"142","author":"Chaudhary","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0610","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2024.101218_bb0615","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101218_bb0620","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0625","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/hematology.2023000435","article-title":"Managing side effects: guidance for use of immunotherapies in multiple myeloma","volume":"2023","author":"Liang","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2024.101218_bb0630","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21113886","article-title":"A new era in endothelial injury syndromes: toxicity of CAR-T cells and the role of immunity","volume":"21","author":"Gavriilaki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2024.101218_bb0635","article-title":"Immune thrombosis: exploring the significance of immune complexes and NETosis","volume":"12","author":"Perdomo","year":"2023","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.blre.2024.101218_bb0640","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1182\/blood-2023-187440","article-title":"Fludarabine lymphodepletion exposure is associated with idecabtagene vicleucel toxicity in relapsed and refractory multiple myeloma patients: real-world experience from the US myeloma immunotherapy consortium","volume":"142","author":"Wagner","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0645","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2024.101218_bb0650","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2024.101218_bb0655","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2024.101218_bb0660","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101218_bb0665","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2024.101218_bb0670","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0675","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006365","article-title":"Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis","volume":"11","author":"Moreno-Castano","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.blre.2024.101218_bb0680","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","article-title":"Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy","volume":"98","author":"Jiang","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2024.101218_bb0685","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2023-187295","article-title":"CAR T-related toxicities based on dynamic proteomic profiles identifies risk factors for cytokine release syndrome (CRS) and immune effector cell -associated neurotoxicity syndrome (ICANS)","volume":"142","author":"Kewan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0690","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood-2023-174506","article-title":"A pro-inflammatory state and peak cytokines are associated with toxicity and early responses in real-world multiple myeloma patients treated with idecabtagene vicleucel","volume":"142","author":"Hansen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0695","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1182\/blood-2023-180128","article-title":"Factors associated with prolonged CRS and neurotoxicity after treatment with axicabtagene ciloleucel","volume":"142","author":"Albittar","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0700","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1182\/blood-2023-179506","article-title":"Easix indices predict CRS and overall survival in adult CAR-T cell recipients","volume":"142","author":"Gavriilaki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0705","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15225443","article-title":"Population-based external validation of the EASIX scores to predict CAR T-cell-related toxicities","volume":"15","author":"de Boer","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2024.101218_bb0710","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/2643-3230.BCD-23-0056","article-title":"Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma","volume":"5","author":"Faramand","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.blre.2024.101218_bb0715","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101218_bb0720","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.blre.2024.101218_bb0725","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2023-179413","article-title":"A comparative analysis of infectious complications in patients with multiple myeloma treated with BCMA-targeted bispecific antibodies and CAR T-cell therapy","volume":"142","author":"Nath","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0730","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101218_bb0735","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2023-187516","article-title":"Infections drive non-relapse mortality following CAR-T therapy across disease entities and CAR products - a meta-analysis of clinical trials and real-world studies","volume":"142","author":"Cordas dos Santos","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0740","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2023-175004","article-title":"Cumulative incidence and characteristics of infections requiring treatment, delay in treatment administration or hospitalisation in patients with relapsed or refractory multiple myeloma treated with anti BCMA or anti GPRC5D bispecific antibodies","volume":"142","author":"Cellerin","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0745","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101218_bb0750","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2023-174443","article-title":"Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial","volume":"142","author":"Richardson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0755","author":"Invivyd Inc"},{"key":"10.1016\/j.blre.2024.101218_bb0760","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clml.2024.03.005","article-title":"Practical aspects of immunotherapy: a report from the 20th international myeloma society (IMS) annual meeting","volume":"24","author":"Raje","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2024.101218_bb0765","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the international myeloma working group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2024.101218_bb0770","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1038\/s41409-021-01383-x","article-title":"The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae","volume":"56","author":"Richardson","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2024.101218_bb0775","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2217\/ijh-2017-0015","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome with multiorgan failure","volume":"6","author":"Richardson","year":"2017","journal-title":"Int J Hematol Oncol"},{"key":"10.1016\/j.blre.2024.101218_bb0780","doi-asserted-by":"crossref","first-page":"8031","DOI":"10.1111\/jcmm.15434","article-title":"Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease","volume":"24","author":"Garcia-Bernal","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.blre.2024.101218_bb0785","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3324\/haematol.2022.281471","article-title":"A phase II, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"108","author":"Hudspeth","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2024.101218_bb0790","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/art.42017","article-title":"Defibrotide inhibits antiphospholipid antibody-mediated neutrophil extracellular trap formation and venous thrombosis","volume":"74","author":"Ali","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.blre.2024.101218_bb0795","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41409-018-0256-8","article-title":"Use of defibrotide to treat adult patients with transplant-associated thrombotic microangiopathy","volume":"54","author":"Martinez-Munoz","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2024.101218_bb0800","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41409-017-0085-1","article-title":"Use of defibrotide to help prevent post-transplant endothelial injury in a genetically predisposed infant with metachromatic leukodystrophy undergoing hematopoietic stem cell gene therapy","volume":"53","author":"Calbi","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl. 4","key":"10.1016\/j.blre.2024.101218_bb0805","first-page":"S74","article-title":"Hyper-inflammation and complement in COVID-19","volume":"98","author":"Pires","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101218_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100995","article-title":"Complement activation in COVID-19 and targeted therapeutic options: a scoping review","volume":"57","author":"Lim","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2024.101218_bb0815","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/bjh.17097","article-title":"COVID-19 infection in patients on anti-complement therapy: the leeds national paroxysmal nocturnal haemoglobinuria service experience","volume":"191","author":"Pike","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2024.101218_bb0820","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10102188","article-title":"Targeting the complement cascade in the pathophysiology of COVID-19 disease","volume":"10","author":"Ng","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2024.101218_bb0825","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jpids\/piaa117","article-title":"Defibrotide for the treatment of pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 infection in 2 pediatric patients","volume":"9","author":"Lang","year":"2020","journal-title":"J Pediatr Infect Dis Soc"},{"key":"10.1016\/j.blre.2024.101218_bb0830","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1182\/blood-2021-147784","article-title":"Use of defibrotide in patients with COVID-19 pneumonia; results of the Defi-VID19 phase 2 trial","volume":"138","author":"Ruggeri","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0835","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.chest.2022.03.046","article-title":"Defibrotide therapy for SARS-CoV-2 ARDS","volume":"162","author":"Frame","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.blre.2024.101218_bb0840","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.284793","article-title":"Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-cell responses","author":"Kocoglu","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2024.101218_bb0845","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.thromres.2023.03.009","article-title":"Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies","volume":"225","author":"Elhadad","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2024.101218_bb0850","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/14728222.2021.1944101","article-title":"Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes","volume":"25","author":"Richardson","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.blre.2024.101218_bb0855","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1182\/bloodadvances.2023009961","article-title":"A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome","volume":"7","author":"Jacobson","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2024.101218_bb0860","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.blre.2024.101218_bb0865","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.1182\/blood-2023-180208","article-title":"Model-based exploration of the impact of prophylactic tocilizumab on IL-6 dynamics in multiple myeloma patients receiving teclistamab treatment","volume":"142","author":"Zhou","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0870","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1182\/blood-2023-189878","article-title":"Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab administration","volume":"142","author":"Marin","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0875","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1182\/blood-2023-187086","article-title":"Tocilizumab prophylaxis for patients treated with teclistamab: a single-center experience","volume":"142","author":"Kowalski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0880","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1200\/JCO.2023.41.16_suppl.8033","article-title":"Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1","volume":"41","author":"van de Donk","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2024.101218_bb0885","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2022-159381","article-title":"Pretreatment with tocilizumab prior to the CD3 bispecific cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) showed a marked reduction in cytokine release syndrome incidence and severity","volume":"140","author":"Trudel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0890","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2024.101218_bb0895","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1177\/10781552221140320","article-title":"Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting","volume":"29","author":"Lipe","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.blre.2024.101218_bb0900","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0905","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood-2021-153987","article-title":"A phase 2\/3 randomized, placebo-controlled, open-label, multi-center trial of lenzilumab to improve the safety and efficacy of CAR-T cell therapy in adults with relapsed or refractory large B-cell lymphoma (the SHIELD study)","volume":"138","author":"Kenderian","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0910","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.thromres.2023.11.021","article-title":"Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: results of a large survey and clinical guidance recommendations from the IFM group","volume":"233","author":"Frenzel","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2024.101218_bb0915","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.blre.2024.101218_bb0920","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2024.101218_bb0925","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122905","volume":"13","author":"Kirschner","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2024.101218_bb0930","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.3390\/jcm11205997","article-title":"Practical recommendations for optimal thromboprophylaxis in patients with COVID-19: a consensus statement based on available clinical trials","volume":"11","author":"Kyriakoulis","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2024.101218_bb0935","author":"Janssen Biotech Inc"},{"key":"10.1016\/j.blre.2024.101218_bb0940","author":"Bristol Myers Squibb"},{"key":"10.1016\/j.blre.2024.101218_bb0945","author":"Jazz Pharmaceuticals Inc"},{"key":"10.1016\/j.blre.2024.101218_bb0950","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S2213-2600(23)00052-8","article-title":"Platform trials: the future of medical research?","volume":"11","author":"Burki","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.blre.2024.101218_bb0955","doi-asserted-by":"crossref","first-page":"S396","DOI":"10.1016\/j.jtct.2023.12.557","article-title":"Metformin and cytokine release syndrome after immune effector cell therapy","volume":"30","author":"Mammadzadeh","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2024.101218_bb0960","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.2174\/0929867329666220729154615","article-title":"Repurposing metformin for vascular disease","volume":"30","author":"Triggle","year":"2023","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.blre.2024.101218_bb0965","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj6251","article-title":"Enhancing the safety of CAR-T cell therapy: synthetic genetic switch for spatiotemporal control","volume":"10","author":"Lu","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.blre.2024.101218_bb0970","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/blood-2023-182430","article-title":"Early safety results of P-BCMA-ALLO1, a fully allogeneic chimeric antigen receptor T-cell (CAR-T), in patients with relapsed \/ refractory multiple myeloma (RRMM)","volume":"142","author":"Dholaria","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb0975","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFNgamma reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.blre.2024.101218_bb0980","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1038\/s41467-023-38723-y","article-title":"Neutralizing IFNgamma improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies","volume":"14","author":"Manni","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2024.101218_bb0985","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s11912-022-01286-0","article-title":"BTK inhibitors and CAR T-cell therapy in treating mantle cell lymphoma-finding a dancing partner","volume":"24","author":"Munoz","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.blre.2024.101218_bb0990","doi-asserted-by":"crossref","DOI":"10.3389\/frhem.2024.1331109","article-title":"How artificial intelligence revolutionizes the world of multiple myeloma","volume":"3","author":"Romero","year":"2024","journal-title":"Front Hematol"},{"key":"10.1016\/j.blre.2024.101218_bb0995","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1097\/01.HS9.0000970388.90596.a3","article-title":"P871 idecabtagene vicleucel (ide-cel) in patients with an inadequate response to frontline autologous stem cell transplantation (ASCT): results from KarMMa-2 cohort 2c","volume":"7","author":"Alsina","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.blre.2024.101218_bb1000","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb1005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.HS9.0000936248.01150.e8","article-title":"P30 single cohort results from MajesTEC-2: teclistamab (tec) in combination with subcutaneous daratumumab (dara) and lenalidomide (len) in patients with multiple myeloma (MM)","volume":"7","author":"Searle","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.blre.2024.101218_bb1010","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000970364.16259.0e","article-title":"P865: teclistamab in combination with lenalidomide in previously treated patients with multiple myeloma in the phase 1B multicohort MajesTEC-2 study","volume":"7","author":"Tan","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.blre.2024.101218_bb1015","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967688.12579.64","article-title":"S194: teclistamab (tec) + nirogacestat (niro) in relapsed\/refractory multiple myeloma (RRMM): the phase 1B MajesTEC-2 study","volume":"7","author":"Offner","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.blre.2024.101218_bb1020","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2024.101218_bb1025","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab + pomalidomide in patients with relapsed\/refractory multiple myeloma: safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb1030","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2023-182388","article-title":"Updated safety and efficacy results of Abbv-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed\/refractory multiple myeloma","volume":"142","author":"Vij","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb1035","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2023-180013","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb1040","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1182\/blood-2023-177968","article-title":"Patterns of response to 200 mg Linvoseltamab in patients with relapsed\/refractory multiple myeloma: longer follow-up of the linker-MM1 study","volume":"142","author":"Jagannath","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb1045","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101218_bb1050","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S2152-2650(22)00342-1","article-title":"P-012: cevostamab is efficacious and well tolerated in patients aged < 65 and \u226565 years with relapsed\/refractory multiple myeloma (RRMM)","volume":"22","author":"Krishnan","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:42:12Z","timestamp":1732149732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X24000511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":210,"alternative-id":["S0268960X24000511"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2024.101218","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2024.101218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101218"}}